{"entity":{"id":"braf-v600-mutation","kind":"term","name":"BRAF V600E mutation","aka":["V600E","V600","BRAF V600E","BRAF V600","BRAF-mutant","BRAF-mutated","BRAF mutation","BRAF-mutant melanoma","BRAF/MEK","BRAF + MEK","class II BRAF","class III BRAF","BRAF inhibitor","MEK inhibitor","BRAF inhibitors","MEK inhibitors"],"tldr":"A single spelling change in the BRAF gene that jams a growth switch permanently on. It is found in half of melanomas and in some colon, thyroid, lung and brain tumours, and is treated with a BRAF pill plus a MEK pill.","summary":"V600E (valine to glutamate at position 600) is the commonest BRAF mutation; class II and III mutations behave differently and resist the same drugs. Dabrafenib-trametinib, encorafenib-binimetinib and vemurafenib-cobimetinib treat metastatic and adjuvant melanoma, with immunotherapy usually given first in metastatic disease (DREAMseq). Encorafenib-cetuximab treats BRAF-mutant colorectal cancer (BEACON), dabrafenib-trametinib has a tumour-agnostic approval including glioma and thyroid cancer, and the combination has moved into paediatric low-grade glioma. BRAF-mutant colorectal cancer is aggressive and often overlaps with MSI-high sporadic tumours.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/BRAF_(gene)","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/BRAF_(gene)"}],"tags":[],"related":["driver-mutation","tumour-agnostic","tki-term"],"cancers":["melanoma","colorectal","thyroid","nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":["braf"],"drugs":["vemurafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/braf-v600-mutation/","neighbours":{"term":[{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/"},{"id":"mlh1-promoter-methylation","kind":"term","name":"MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)","route":"/terms/mlh1-promoter-methylation/"},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/"},{"id":"tki-term","kind":"term","name":"Tyrosine kinase inhibitor (TKI)","route":"/terms/tki-term/"}],"cancer":[{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/"},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"}],"drug":[{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/"}],"trial":[{"id":"brf113928","kind":"trial","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","route":"/trials/brf113928/"},{"id":"pharos","kind":"trial","name":"PHAROS","route":"/trials/pharos/"},{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/"}],"biomarker":[{"id":"braf-class-ii-iii","kind":"biomarker","name":"BRAF class II and class III mutations (non-V600)","route":"/biomarkers/braf-class-ii-iii/"},{"id":"braf-fusion","kind":"biomarker","name":"BRAF fusion or rearrangement","route":"/biomarkers/braf-fusion/"},{"id":"braf-v600e","kind":"biomarker","name":"BRAF V600E (and V600K)","route":"/biomarkers/braf-v600e/"}]}}